🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Sonelokimab

    MoonLake Immunotherapeutics

    Relative Bioequivalence

    phase 1 small molecule completed

    1 trial

  2. Sonodynamic therapy (SDT)

    The First People's Hospital of Lianyungang

    Carotid Atherosclerosis

    phase 1 other completed

    1 trial

  3. Stelara

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  5. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  6. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  7. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  8. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  9. Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  10. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  11. Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or refractory multiple myeloma

    phase 1 other active

    1 trial

  12. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  13. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel Therapeutics

    Agitation

    phase 1 small molecule completed

    1 trial

  14. Sulfasalazine

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Sulopenem

    Iterum Therapeutics plc

    Urinary Tract Infections

    phase 1 small molecule terminated

    1 trial

  16. TAF/EVG Vaginal Insert

    United Therapeutics Europe Ltd

    Hiv

    phase 1 small molecule completed

    1 trial

  17. TAF/EVG vaginal insert

    United Therapeutics Europe Ltd

    Safety Issues

    phase 1 small molecule completed

    1 trial

  18. TAK-137

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 1 small molecule terminated

    1 trial

  19. TAK-659

    Nektar Therapeutics UK Limited

    Lymphoma, Non-Hodgkin

    phase 1 small molecule terminated

    1 trial

  20. TBP-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. TBP-PI-HBr

    Spero Therapeutics

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  22. TBPM-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  23. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  24. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources